salicylates and Poultry-Diseases

A 42-d floor pen study was conducted with broiler chickens comparing the effects on bird performance of 12 ppm TAMUS 2032 (also known as BT) and 55 ppm bacitracin methylene disalicyclate (BMD) when fed alone or in combination with 99 ppm monensin (MON). Unmedicated and 99 ppm MON treatments were included in the study design. Beginning on d 22 of study, birds in all 6 treatments were subjected to a modulated house temperature and airflow to mimic conditions conducive to outbreaks of colibacillosis. A natural outbreak of colibacillosis developed beginning on d 27. Primary lesions in dead birds included airsacculitis and pericarditis with occasional findings of perihepatitis. At d 42 of study, means for weight gain in the TAMUS 2032 and TAMUS 2032 + MON treatments were greater in comparison with the unmedicated and BMD treatments, and means for feed conversion for both treatments were improved in comparison with the unmedicated treatment. Mean feed conversion in the TAMUS 2032 + MON treatment was also improved in comparison with BMD treatment. Mortality due to colibacillosis was reduced in the TAMUS 2032 (0.051%), TAMUS 2032 + MON (0.642%), and MON + BMD (1.515%) treatments in comparison with the unmedicated treatment (13.402%) and the BMD treatment (11.159%). The results of improved performance and reduced mortality indicated that 12 ppm TAMUS 2032 was highly efficacious against colibacillosis in growing chickens. The reduced mortality percentages in the MON + BMD treatment indicated that this combination also provided a good level of protection against the natural outbreak of colibacillosis.

Topics: Animals; Bacitracin; Chickens; Disease Outbreaks; Drug Therapy, Combination; Escherichia coli Infections; Female; Hepatitis, Animal; Hot Temperature; Housing, Animal; Male; Monensin; Oligopeptides; Pericarditis; Poultry Diseases; Salicylates; Ventilation

The efficacy of bacitracin methylene disalicylate (BMD) in the management of necrotic enteritis (NE) when fed in combination with narasin was investigated in a floor-pen study of 2,000 broiler chickens using a Clostridium perfringens inoculum challenge model. Treatments consisted of 1) nonchallenged-nonmedicated; 2) challenged-nonmedicated; 3) challenged-narasin (70 ppm); 4) challenged-BMD (55 ppm); 5) challenged-narasin (70 ppm) + BMD (55 ppm). Medication was provided in the feed from Day 0 to trial termination on Day 41. C. perfringens challenge occurred from Day 14 to 16. BMD and narasin, fed alone and in combination, reduced (P < 0.05) mortality due to NE when compared to challenged-nonmedicated birds. NE lesion scores (Days 0 through 41) were lower among birds fed BMD and narasin, alone and in combination, compared to challenged-nonmedicated birds. Improvements in NE mortality and NE lesion scores were greatest for the BMD + narasin-medicated birds, followed by the BMD-alone, and then narasin-alone treated birds. BMD and narasin, alone and in combination, provided improvements (P < 0.05) in average daily gains over the entire study (Days 0 to 41). The results of this study demonstrate the effectiveness of BMD and narasin in the management of NE in broiler chickens.

Topics: Animals; Anti-Bacterial Agents; Bacitracin; Chickens; Clostridium Infections; Clostridium perfringens; Enteritis; Male; Necrosis; Poultry Diseases; Pyrans; Salicylates; Weight Gain

Three hundred and sixty 1-day-old male broiler chicks were randomly allocated to 4 treatments of 6 replicates to evaluate the effects of cLFchimera, a recombinant antimicrobial peptide (AMP), on gut health attributes of broiler chickens under necrotic enteritis (NE) challenge. Treatments were as follows: (T1) unchallenged group fed with corn-soybean meal (CSM) without NE challenge and additives (NC); (T2) group fed with CSM and challenged with NE without any additives (PC); (T3) PC group supplemented with 20 mg cLFchimera/kg diet (AMP); (T4) PC group supplemented with 45 mg antibiotic (bacitracin methylene disalicylate)/kg diet (antibiotic). Birds were sampled for villi morphology, ileal microbiota, and jejunal gene expression of cytokines, tight junctions proteins, and mucin. Results showed that AMP ameliorated NE-related intestinal lesions, reduced mortality, and rehabilitated jejunal villi morphology in NE challenged birds. While the antibiotic non-selectively reduced the count of bacteria, AMP restored microflora balance in the ileum of challenged birds. cLFchimera regulated the expression of cytokines, junctional proteins, and mucin transcripts in the jejunum of NE challenged birds. In conclusion, cLFchimera can be a reliable candidate to substitute growth promoter antibiotics, while more research is required to unveil the exact mode of action of this synthetic peptide.

Topics: Amino Acid Sequence; Animal Feed; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacitracin; Chickens; Colony Count, Microbial; Enterocolitis, Necrotizing; Gastrointestinal Microbiome; Jejunum; Poultry Diseases; Recombinant Proteins; Salicylates

Necrotic enteritis toxin B (NetB)-producing Clostridium perfringens (CP) type A is the etiological agent of necrotic enteritis (NE) - an economically significant disease in broiler chickens. Understanding the immune response to CP infection in broiler chickens is becoming important to develop effective vaccines against NE. An experiment was conducted to determine the expression levels of selected cytokine genes in the intestine and cecal tonsil of CP-challenged broiler chickens. In a floor-pen housing, broiler chickens were randomly assigned to the following treatment groups: 1) bacitracin methylene disalicylate (BMD)-free control diet with no CP challenge (CX), 2) BMD-supplemented diet with no CP challenge (CM), 3) BMD-free control diet with CP challenge (PCX), or 4) BMD-supplemented diet with CP challenge (PCM). The establishment of CP infection was confirmed, with the treatment groups exposed to CP having a 1.5 to 2-fold higher CP levels (P < 0.05) compared to the non-exposed groups. On day 1 and 7 post-challenge, jejunal segments and cecal tonsils were collected from experimental chickens for quantitative real-time RT-PCR analysis to determine the expression levels of interleukin (IL)-1β, interferon-γ (IFN-γ), IL-2, IL-13, IL-17, IL-10, and transforming growth factor (TGF)-β genes. Levels of antibodies to CP recombinant proteins were also determined in the plasma of experimental chickens. Results indicated that on day 7 post-challenge, IL-1β (proinflammatory cytokine), IL-13 (Th2 cytokine), and IL-17 (Th17 cytokine) were upregulated (P < 0.05) in CP-challenged PCX and PCM treatments, compared to the unchallenged (control) CX and CM treatments. A reverse trend was observed for TGF-β (anti-inflammatory cytokine), while no change was observed in IFN-γ (Th1 cytokine). Levels of plasma antibodies (IgY) to CP recombinant proteins were higher in CP-challenged treatments (PCX and PCM; P < 0.05), compared to their corresponding controls (CX and CM). It was concluded that CP infection induced inflammatory response in the intestine of broiler chickens, and the mechanisms of inflammation are probably mediated via Th2 and Th17 cells.

Topics: Animals; Anti-Bacterial Agents; Bacitracin; Chickens; Clostridium Infections; Clostridium perfringens; Cytokines; Enteritis; Immunoglobulins; Intestines; Poultry Diseases; Salicylates; Transcriptome

The effect of dietary inclusion of Bacillus subtilis DSM 32315 on the intestinal health and growth performance of Cobb 500 male broilers subjected to a Clostridium perfringens-induced necrotic enteritis (NE) challenge was determined in 2 experiments. In experiment 1, chicks were randomly assigned to 4 treatments of 10 replicate/treatment. In experiment 2, chicks were randomly assigned to 4 treatments of 12 replicates/treatment. The experimental treatments were non-infected, non-supplemented control, infected, non-supplemented control (IC), infected + Bacillus subtilis DSM 32315 (B. subtilis DSM 32315), infected + bacitracin methylene disalicylate (BMD). In both experiments, NE was induced by oral inoculation of toxin producing C. perfringens on 3 consecutive days between 17 and 20 D of age, following exposure of birds to pre-disposing conditions. At day 28 (experiment 1), broilers fed diets with B. subtilis DSM 32315 exhibited a significantly higher body weight, lower mortality, and intestinal NE lesion score, compared to the IC treatment. At day 42 (experiment 2), B. subtilis DSM 32315 supplementation significantly improved BW, feed conversion ratio, production efficiency factor, NE lesion score, and mortality, compared to IC treatment. The effect of B. subtilis DSM 32315 on intestinal integrity of NE challenged chickens was evaluated with histomorphometry. A significantly shallower crypt depth and higher villus height to crypt depth ratio were observed in the mid-intestine of birds belonging to the B. subtilis DSM 32315 group, compared to the IC group. Furthermore, B. subtilis DSM 32315 supplementation significantly reduced the enteritis index associated with NE. In both experiments, the effect of B. subtilis DSM 32315 on the phenotypic measurements of NE and performance was comparable to the effect observed with BMD supplementation. In conclusion, supplementation of the direct fed microbial strain B. subtilis DSM 32315 can ameliorate the pathology and performance detriments associated with NE.

Topics: Animal Feed; Animals; Anti-Bacterial Agents; Bacillus subtilis; Bacitracin; Chickens; Clostridium Infections; Clostridium perfringens; Diet; Enteritis; Intestines; Male; Necrosis; Poultry Diseases; Probiotics; Salicylates

This experiment was conducted to evaluate the effect of Bacillus subtilis (BS) on broiler performance and health after intramuscular inoculation with E. coli and compare its effect with a growth promoter antibiotic. In a completely randomized design manner, 360 male Ross 308 chicks were divided into 6 treatments and 5 replicates of 12 chicks in each replicate. Experimental treatments included control diet, control + E. coli (0.5 mL of culture containing 108 CFU of E. coli/ml), control + 0.1% BS, control + 0.05% bacitracin methylene disalicylate (BMD), control + E. coli and BS, and control + E. coli and BMD in a factorial arrangement (3 × 2). Addition of BMD or BS to the control diet significantly (P < 0.01) increased body weight and decreased FCR, but E. coli challenge adversely reduced (P < 0.01) body weight and increased FCR, so that the addition of BMD or BS did not compensate growth reduction. E. coli challenged chicks had the lowest vaccine titers for ND, IB, AI, and IBD and the highest were observed in chicks fed BS. The E. coli challenge significantly (P < 0.01) increased albumin, globulin, cholesterol, triglyceride, LDL, ALT, and ALP indices. Addition of BMD and BS decreased albumin and globulin in challenged chick's plasma but had no effect on plasma lipid profile concentration. The E. coli challenge decreased villus height and increased crypt depth and goblet cell numbers significantly (P < 0.01). In birds subjected to BMD or BS, crypt depth decreased and villus height increased (P < 0.01), compared with the control diet. Challenge of E. coli significantly (P < 0.01) increased the bacterial population of E. coli, coliforms, and Salmonella in cecal parts of broilers' intestines. In challenged birds receiving BMD or BS, E. coli, coliform, and Salmonella populations of ceca showed a significant (P < 0.01) reduction. Both BMD and BS increased the digestibility of nutrients significantly (P < 0.01), but a reduction was observed in E. coli challenged groups. Results of the study suggest that spore-forming probiotics are partially effective in unsuitable rearing situations such as colibacillosis in which the load of harmful bacteria is high.

Topics: Animal Feed; Animals; Anti-Bacterial Agents; Bacillus subtilis; Bacitracin; Body Weight Maintenance; Chickens; Diet; Escherichia coli; Escherichia coli Infections; Gastrointestinal Microbiome; Male; Poultry Diseases; Probiotics; Salicylates; Vaccination

Avi-Lution® is a defined, patented, synbiotic product containing Saccharomyces cerevisiae, Enterococcus faecium, and Bacillus spp. Broiler chickens (n = 1,250) were experimentally treated as uninoculated controls (uCon), inoculated controls (iCon) with Clostridium perfringens, or inoculated and treated with bacitracin methylene disalicylate (BMD) at 55 mg/kg as an infected/treated control or Avi-Lution® at 1.0 (AvL1) or 2.0 (AvL2) g/kg in feed for 42 d. Each treatment was applied to 10 replicate pens of 25 straight-run, newly hatched chicks. Pens treated with AvL1, AvL2, or BMD showed improved growth, feed efficiency, or mortality from necrotic enteritis compared with iCon pens at d 14, 28, and 42. No differences in these measurements, however, were observed between pens treated with AvL1 and AvL2, which suggests that Avi-Lution® was effective at 1.0 g/kg in feed. Despite improved performance, BMD, AvL1, and AvL2 treatments did not decrease the severity of intestinal lesion scores through 42 d of age compared with the infected control. These results demonstrate that Avi-Lution® improved growth performance and feed conversion rates in broilers challenged with Clostridium perfringens despite no difference in severity of intestinal lesion scores.

Topics: Animal Feed; Animals; Bacillus; Bacitracin; Chickens; Clostridium Infections; Clostridium perfringens; Diet; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterococcus faecium; Male; Poultry Diseases; Random Allocation; Saccharomyces cerevisiae; Salicylates; Synbiotics

The virulence of a Salmonella enterica serovar Typhimurium DT014 strain in which marA was insertionally inactivated was compared to its isogenic parent in vitro and in vivo. In vitro, the numbers of the marA mutant phagocytosed by porcine lung macrophages were significantly increased, while survival at 24 h inside macrophages and adherence to human gut cells were significantly reduced in comparison with the parent strain. In vivo, the marA inactivated strain, in competition with its parent strain, persisted for a shorter period in chickens, was present in the caeca at significantly lower levels and invaded the deeper organs to a significantly lesser extent. Therapeutic antibiotic treatment of one group of chickens with oxytetracycline favoured the persistence of both the parent strain and, to a lesser extent, the marA inactivated strain; but interestingly, increased tetracycline resistance of Salmonella isolates after treatment of birds with antibiotic was seen only for the parent strain. Further work is needed to elucidate how mar is involved in virulence and if its inactivation can minimise the ability of bacteria to become antibiotic-resistant in vivo.

Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Cecum; Cell Line; Chickens; Disease Models, Animal; DNA-Binding Proteins; Escherichia coli Proteins; Humans; Intestinal Mucosa; Liver; Macrophages, Alveolar; Mutagenesis, Insertional; Phagocytosis; Poultry Diseases; Salicylates; Salmonella Infections, Animal; Salmonella typhimurium; Specific Pathogen-Free Organisms; Spleen; Swine; Virulence

Two similar trials were conducted to evaluate the effects of dietary inclusion of fructooligosaccharide (FOS) on live performance and carcass characteristics of broilers and on incidence and level of salmonellae on prechill broiler carcasses. The FOS was fed at two levels (0 and .375%) in a complete factorial arrangement with two levels (0 and 55 mg/kg) of bacitracin methylene disalicylate (BMD) in nutritionally complete diets. Broilers were grown to 49 days of age, and samples were processed to determine dressing percentage, abdominal fat content, and most probable number salmonellae on prechill carcasses. The addition of FOS to nutritionally complete broiler diets at .375% had little consistent effect on growth rate, feed utilization, mortality, carcass dressing percentage, abdominal fat content, or incidence or severity of salmonellae contamination of processed broiler carcasses. There appeared to be an antagonism between FOS and BMD on both live performance and salmonellae contamination of processed broiler carcasses.

Topics: Animal Feed; Animals; Bacitracin; Chickens; Coccidiostats; Colony Count, Microbial; Dietary Carbohydrates; Evaluation Studies as Topic; Female; Male; Oligosaccharides; Poultry Diseases; Salicylates; Salmonella Infections, Animal; Salmonella typhimurium

A total of 879 broiler strain chickens ranging from 2 1/2- to 7 1/2 weeks of age was utilized in four battery experiments to determine whether Roxarsone and/or bacitracin MD added to halofuginone were compatible and beneficial in reducing the effects of coccidial infections. The additives were generally beneficial as measured by weight gain and feed efficiency but not as measured by other parameters such as dropping score, lesion score, or oocyst production. The addition of 200 g of bacitracin/ton of feed did not give an additional response above that from 50 g/ton. Roxarsone in the ration was more effective in younger chickens (2 1/2 week old) than older ones (6 weeks, 2 days and 7 weeks, 3 days).

Topics: Animals; Arsenicals; Bacitracin; Body Weight; Chickens; Coccidiosis; Coccidiostats; Drug Combinations; Eimeria; Feeding Behavior; Piperidines; Poultry Diseases; Quinazolines; Quinazolinones; Roxarsone; Salicylates

Topics: Acetylcholine; Anaphylaxis; Anesthesia, Intravenous; Animals; Atropine; Blood Pressure; Chickens; Chloral Hydrate; Chlorpheniramine; Epinephrine; Female; Flumethasone; Hexamethonium Compounds; Histamine; Norepinephrine; p-Methoxy-N-methylphenethylamine; Pentobarbital; Poultry Diseases; Promethazine; Salicylates; Serum Albumin, Bovine; Tripelennamine

Topics: Administration, Oral; Age Factors; Animals; Antiprotozoal Agents; Diet; Female; Hydrazines; Male; Nitrofurans; Poultry Diseases; Protozoan Infections; Salicylates; Turkeys

Topics: Acetamides; Animals; Antiprotozoal Agents; Copper; Hydrazines; Imidazoles; Nitro Compounds; Nitrofurans; Poultry Diseases; Protozoan Infections; Salicylates; Sulfates; Thiazoles; Turkeys

Topics: Animal Feed; Animals; Antiprotozoal Agents; Evaluation Studies as Topic; Food Additives; Hydrazines; Methods; Nitrofurans; Poultry Diseases; Protozoan Infections; Quality Control; Salicylates; Spectrophotometry